Temelimab

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Temelimab (also known as GNbAC1 ) is an experimental monoclonal antibody drug for immune system conditions that neutralizes the human endogenous retrovirus envelope protein HERV-W. It has been studied for multiple sclerosis up to phase 2b, where it was found to be safe and to reduce brain lesions. As of 2023, it is also being studied for cognitive impairment in long COVID.

Temelimab (also known as GNbAC1 ) is an experimental monoclonal antibody drug for immune system conditions that neutralizes the human endogenous retrovirus envelope protein HERV-W. It has been studied for multiple sclerosis up to phase 2b, where it was found to be safe and to reduce brain lesions. As of 2023, it is also being studied for cognitive impairment in long COVID.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1314723418 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.